A recent study from the Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Bad Nauheim, Germany shows that “Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in T2DM.” This study was published in the 12 January 2015 issue of Nature Medicine by Drs. Tang C, Offermanns S, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based molecular therapy for T2DM: Stem cell protein Oct-4 promotes insulin secretion and inhibits glucose intolerance via down regulation of FFA2 and FFA3. This study suggests, for the first time, that Oct-4, by increasing the expression of its target gene, it may down regulate the expression of FFA2 and FFA3. Thereby, it may increase insulin secretion and alleviate glucose intolerance. Together, pharmacological formulations encompassing “Oct-4 activators” may be used to increase insulin sensitivity and treat T2DM.
Amount: $ 500
Undisclosed information: How Oct4 suppresses the expression of FFA2 and FFA3
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based molecular therapy for T2DM: Stem cell protein Oct-4 promotes insulin secretion and glucose intolerance via down regulation of FFA2 and FFA3, 17/November/2014, 10.58 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
